Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials
Gary Lichtenstein(University of Pennsylvania), William J. Sandborn(University of San Diego), Yinghua Lang, Colleen Marano(Johnson & Johnson (United States)), Carrie Wagner(Johnson University), Robert H. Diamond, Adedigbo A. Fasanmade(TetraLogic Pharmaceuticals (United States)), Jewel Johanns(Johnson & Johnson (United States)), A. Olson
Cited by 195
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k